

# Bertram Pitt

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/421370/publications.pdf>

Version: 2024-02-01

257  
papers

33,763  
citations

21215

62  
h-index

4414

178  
g-index

261  
all docs

261  
docs citations

261  
times ranked

18280  
citing authors

#	ARTICLE	IF	CITATIONS
1	Kidney outcomes with finerenone: an analysis from the FIGARO-DKD study. <i>Nephrology Dialysis Transplantation</i> , 2023, 38, 372-383.	0.4	13
2	Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 1014-1023.	0.4	50
3	Why are mineralocorticoid receptor antagonists the Cinderella in evidence-based treatment of myocardial infarction complicated with heart failure? Lessons from PARADISE-MI. <i>European Heart Journal</i> , 2022, 43, 1428-1431.	1.0	10
4	Effects of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction patients with chronic obstructive pulmonary disease in <sc>EMPHASISâ€HF</sc> and <sc>RALES</sc>. <i>European Journal of Heart Failure</i> , 2022, 24, 529-538.	2.9	7
5	Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by <sc>GLPâ€RA</sc> treatment: A subgroup analysis from the <sc>FIDELIOâ€DKD</sc> trial. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 125-134.	2.2	41
6	Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy. <i>Kidney International Reports</i> , 2022, 7, 36-45.	0.4	73
7	Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. <i>European Heart Journal</i> , 2022, 43, 474-484.	1.0	341
8	OUP accepted manuscript. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2022, , .	0.4	2
9	The Role of Combined SGLT1/SGLT2 Inhibition in Reducing the Incidence of Stroke and Myocardial Infarction in Patients with Type 2 Diabetes Mellitus. <i>Cardiovascular Drugs and Therapy</i> , 2022, 36, 561-567.	1.3	16
10	Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2022, 33, 225-237.	3.0	89
11	Weight changes in heart failure with preserved ejection fraction: findings from TOPCAT. <i>Clinical Research in Cardiology</i> , 2022, 111, 451-459.	1.5	6
12	Patiromer for the management of hyperkalaemia in patients receiving reninâ€angiotensinâ€aldosterone system inhibitors for heart failure: design and rationale of the <sc>DIAMOND</sc> trial. <i>European Journal of Heart Failure</i> , 2022, 24, 230-238.	2.9	32
13	Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory <i>post hoc</i> analyses from FIDELIO-DKD compared to reported CREDENCE results. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 1261-1269.	0.4	32
14	Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial. <i>Circulation</i> , 2022, 145, 437-447.	1.6	86
15	Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study. <i>Diabetes Care</i> , 2022, 45, e888-e897.	4.3	20
16	Cardiac structure and function and quality of life associations in HFpEF: An analysis from TOPCAT-Americas. <i>International Journal of Cardiology</i> , 2022, 352, 78-83.	0.8	2
17	A promise unfulfilled: the use of mineralocorticoid receptor antagonists in patients with heart failure and a reduced left ventricular ejection fraction. <i>European Journal of Heart Failure</i> , 2022, 24, 548-550.	2.9	1
18	Repurposing low-dose naltrexone for the prevention and treatment of immunothrombosis in COVID-19. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 402-405.	1.4	11

#	ARTICLE	IF	CITATIONS
19	Is it time to shift our focus from treatment to prevention of heart failure with a mineralocorticoid receptor antagonist?. European Journal of Heart Failure, 2022, 24, 631-633.	2.9	0
20	Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the <sc>FIDELIOâ€œDKD</sc> trial. European Journal of Heart Failure, 2022, 24, 996-1005.	2.9	23
21	Influence of race in the estimation of glomerular filtration rate in patients with a high cardiovascular and renal risk. CKJ: Clinical Kidney Journal, 2022, 15, 822-824.	1.4	2
22	MO198: Outcomes with Finerenone in Patients with Stage 4 Chronic Kidney Disease and Type 2 Diabetes: A Fidelity Subgroup Analysis. Nephrology Dialysis Transplantation, 2022, 37, .	0.4	0
23	Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure With Reduced Ejection Fraction: DEFINE-HF. Circulation, 2022, 146, 808-818.	1.6	33
24	Non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease. European Heart Journal, 2022, 43, 2931-2945.	1.0	14
25	Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. New England Journal of Medicine, 2021, 384, 117-128.	13.9	1,080
26	Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. New England Journal of Medicine, 2021, 384, 129-139.	13.9	662
27	Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes. Circulation, 2021, 143, 540-552.	1.6	171
28	Detection of patients at risk of developing heart failure responsive to mineralocorticoid receptor antagonists (MRAs): new insights and opportunities. European Heart Journal, 2021, 42, 697-699.	1.0	4
29	ARNI and MRA Combination in PARAGON-HF. JACC: Heart Failure, 2021, 9, 25-27.	1.9	1
30	Impact of diabetes on serum biomarkers in heart failure with preserved ejection fraction: insights from the TOPCAT trial. ESC Heart Failure, 2021, 8, 1130-1138.	1.4	21
31	Estimated plasma volume status in heart failure: clinical implications and future directions. Clinical Research in Cardiology, 2021, 110, 1159-1172.	1.5	30
32	Spirolactone in Patients With Heart Failure, Preserved Ejection Fraction, and Worsening Renal Function. Journal of the American College of Cardiology, 2021, 77, 1211-1221.	1.2	19
33	Heart failure re-hospitalizations and subsequent fatal events in coronary artery disease: insights from COMMANDER-HF, EPHEBUS, and EXAMINE. Clinical Research in Cardiology, 2021, 110, 1554-1563.	1.5	5
34	Dapagliflozin effects on lung fluid volumes in patients with heart failure and reduced ejection fraction: Results from the <sc>DEFINEâ€œHF</sc> trial. Diabetes, Obesity and Metabolism, 2021, 23, 1426-1430.	2.2	14
35	Pragmatic Design of Randomized Clinical Trials for Heart Failure. JACC: Heart Failure, 2021, 9, 325-335.	1.9	22
36	Potential repurposing of the HDAC inhibitor valproic acid for patients with COVID-19. European Journal of Pharmacology, 2021, 898, 173988.	1.7	31

#	ARTICLE	IF	CITATIONS
37	Diuretic therapy as prognostic enrichment factor for clinical trials in patients with heart failure with reduced ejection fraction. <i>Clinical Research in Cardiology</i> , 2021, 110, 1308-1320.	1.5	3
38	FC 090EFFECTS OF FINERENONE ON CARDIORENAL OUTCOMES IN BLOOD PRESSURE SUBGROUPS IN PATIENTS WITH CKD AND T2D. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.4	2
39	What can heart failure trialists learn from oncology trialists?. <i>European Heart Journal</i> , 2021, 42, 2373-2383.	1.0	9
40	Impact of Insulin Treatment on the Effect of Eplerenone: Insights From the EMPHASIS-HF Trial. <i>Circulation: Heart Failure</i> , 2021, 14, e008075.	1.6	3
41	Serum microRNAs and antifibrotic response to eplerenone in acute myocardial infarction complicated by systolic dysfunction. <i>International Journal of Cardiology</i> , 2021, 332, 35-37.	0.8	4
42	New frontiers in pharmacologic obstructive sleep apnea treatment: A narrative review. <i>Sleep Medicine Reviews</i> , 2021, 57, 101473.	3.8	22
43	Heart Failure and Chronic Kidney Disease Patients. <i>Journal of the American College of Cardiology</i> , 2021, 78, 344-347.	1.2	4
44	Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes. <i>Journal of the American College of Cardiology</i> , 2021, 78, 142-152.	1.2	74
45	Effect of KBP-5074 on Blood Pressure in Advanced Chronic Kidney Disease: Results of the BLOCK-CKD Study. <i>Hypertension</i> , 2021, 78, 74-81.	1.3	59
46	Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2021, 385, 2252-2263.	13.9	599
47	Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure. <i>Annals of Internal Medicine</i> , 2021, 174, 1065-1072.	2.0	32
48	A preliminary study on the relationship between sleep, depression and cardiovascular dysfunction in a 4 sample population. <i>IJC Heart and Vasculature</i> , 2021, 35, 100814.	0.6	0
49	Target trial emulations: bridging the gap between clinical trial and real world data. <i>European Journal of Heart Failure</i> , 2021, 23, 1708-1711.	2.9	1
50	An evaluation of KBP-5074 in advanced chronic kidney disease with uncontrolled hypertension. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 1017-1023.	1.9	10
51	Is Spironolactone the Preferred Renin-Angiotensin-Aldosterone Inhibitor for Protection Against COVID-19?. <i>Journal of Cardiovascular Pharmacology</i> , 2021, 77, 323-331.	0.8	20
52	SGLT-2 inhibitors in heart failure: Time for broader eligibility and earlier initiation. <i>Cleveland Clinic Journal of Medicine</i> , 2021, 88, 601-606.	0.6	2
53	Outpatient diuretic intensification as endpoint in heart failure with preserved ejection fraction trials: an analysis from TOPCAT. <i>European Journal of Heart Failure</i> , 2021, , .	2.9	5
54	Determinants of anti-fibrotic response to mineralocorticoid receptor antagonist therapy: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) and Early Eplerenone Treatment in Patients with Acute ST-elevation Myocardial Infarction without Heart Failure (REMINDER) trials. <i>Clinical Research in Cardiology</i> , 2020, 109, 194-204.	1.5	19

#	ARTICLE	IF	CITATIONS
55	Mineralocorticoid Receptor Antagonists, Blood Pressure, and Outcomes in Heart Failure With Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , 2020, 8, 188-198.	1.9	38
56	Cardiovascular risk associated with serum potassium in the context of mineralocorticoid receptor antagonist use in patients with heart failure and left ventricular dysfunction. <i>European Journal of Heart Failure</i> , 2020, 22, 1402-1411.	2.9	19
57	Visit-to-visit blood pressure variation and outcomes in heart failure with reduced ejection fraction: findings from the Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms trial. <i>Journal of Hypertension</i> , 2020, 38, 420-425.	0.3	12
58	Medical Therapies for Heart Failure With Preserved Ejection Fraction. <i>Hypertension</i> , 2020, 75, 23-32.	1.3	61
59	Primary Aldosteronism. <i>JACC: Cardiovascular Imaging</i> , 2020, 13, 2160-2161.	2.3	2
60	Associations Between Depressive Symptoms and HFpEF-Related Outcomes. <i>JACC: Heart Failure</i> , 2020, 8, 1009-1020.	1.9	19
61	Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2020, 383, 2219-2229.	13.9	1,148
62	Pathophysiology of Diuretic Resistance and Its Implications for the Management of Chronic Heart Failure. <i>Hypertension</i> , 2020, 76, 1045-1054.	1.3	67
63	Spironolactone dose in heart failure with preserved ejection fraction: findings from TOPCAT. <i>European Journal of Heart Failure</i> , 2020, 22, 1615-1624.	2.9	24
64	Myocardial Infarction in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2020, 8, 618-626.	1.9	17
65	Mineralocorticoid Receptor Antagonists for Hypertension Management in Advanced Chronic Kidney Disease. <i>Hypertension</i> , 2020, 76, 144-149.	1.3	27
66	Abnormalities of Potassium in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2836-2850.	1.2	94
67	Myocardial reperfusion reverses the J-curve association of cardiovascular risk and diastolic blood pressure in patients with left ventricular dysfunction and heart failure after myocardial infarction: insights from the EPHEsus trial. <i>European Heart Journal</i> , 2020, 41, 1673-1683.	1.0	39
68	Sex differences in mineralocorticoid receptor antagonist trials: a pooled analysis of three large clinical trials. <i>European Journal of Heart Failure</i> , 2020, 22, 834-844.	2.9	36
69	Association between potassium level and outcomes in heart failure with reduced ejection fraction: a cohort study from the Swedish Heart Failure Registry. <i>European Journal of Heart Failure</i> , 2020, 22, 1390-1398.	2.9	33
70	Predictors of sudden cardiac death in high-risk patients following a myocardial infarction. <i>European Journal of Heart Failure</i> , 2020, 22, 848-855.	2.9	14
71	Mechanistic Effects of Spironolactone on Cardiovascular and Renal Biomarkers in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2020, 13, e006638.	1.6	12
72	Prognostic impact of plasma volume estimated from hemoglobin and hematocrit in heart failure with preserved ejection fraction. <i>Clinical Research in Cardiology</i> , 2020, 109, 1392-1401.	1.5	21

#	ARTICLE	IF	CITATIONS
73	Eplerenone prevents an increase in serum carboxy-terminal propeptide of procollagen type I after myocardial infarction complicated by left ventricular dysfunction and/or heart failure. <i>European Journal of Heart Failure</i> , 2020, 22, 901-903.	2.9	8
74	Trends in Treatment for Patients Hospitalized with Heart Failure with Preserved Ejection Fraction Before and After Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT). <i>American Journal of Cardiology</i> , 2020, 125, 1655-1660.	0.7	7
75	Interactions between left ventricular ejection fraction, sex and effect of neurohumoral modulators in heart failure. <i>European Journal of Heart Failure</i> , 2020, 22, 898-901.	2.9	59
76	Impact of Malnutrition Using Geriatric Nutritional Risk Index in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2019, 7, 664-675.	1.9	68
77	Application of the H <sub>2</sub> FPEF score to a global clinical trial of patients with heart failure with preserved ejection fraction: the TOPCAT trial. <i>European Journal of Heart Failure</i> , 2019, 21, 1288-1291.	2.9	18
78	Age-Related Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2019, 74, 601-612.	1.2	97
79	Eplerenone in patients with myocardial infarction and a range of ejection fraction: An analysis from the EPHEsus trial. <i>Clinical Cardiology</i> , 2019, 42, 1106-1112.	0.7	13
80	Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial. <i>American Journal of Nephrology</i> , 2019, 50, 345-356.	1.4	127
81	Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial. <i>American Journal of Nephrology</i> , 2019, 50, 333-344.	1.4	112
82	Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction. <i>Circulation</i> , 2019, 140, 1463-1476.	1.6	279
83	Utility of the Cardiovascular Physical Examination and Impact of Spironolactone in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2019, 12, e006125.	1.6	21
84	Potassium binders for the prevention of hyperkalaemia in heart failure patients: implementation issues and future developments. <i>European Heart Journal Supplements</i> , 2019, 21, A55-A60.	0.0	17
85	N-Terminal Pro-B-Type Natriuretic Peptide Levels for Risk Prediction in Patients With Heart Failure and Preserved Ejection Fraction According to Atrial Fibrillation Status. <i>Circulation: Heart Failure</i> , 2019, 12, e005766.	1.6	21
86	Mean BMI, visit-to-visit BMI variability and BMI changes during follow-up in patients with acute myocardial infarction with systolic dysfunction and/or heart failure: insights from the High-Risk Myocardial Infarction Initiative. <i>Clinical Research in Cardiology</i> , 2019, 108, 1215-1225.	1.5	17
87	The renin-angiotensin-aldosterone system and its suppression. <i>Journal of Veterinary Internal Medicine</i> , 2019, 33, 363-382.	0.6	251
88	Renal function stratified dose comparisons of eplerenone versus placebo in the EMPHASIS-HF trial. <i>European Journal of Heart Failure</i> , 2019, 21, 345-351.	2.9	43
89	Income level and inequality as complement to geographical differences in cardiovascular trials. <i>American Heart Journal</i> , 2019, 218, 66-74.	1.2	23
90	MRAs in Elderly HF Patients. <i>JACC: Heart Failure</i> , 2019, 7, 1012-1021.	1.9	33

#	ARTICLE	IF	CITATIONS
91	Sex-Related Differences in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2019, 12, e006539.	1.6	78
92	Incidence, Predictors, and Outcome Associations of Dyskalemia in Heart Failure With Preserved, Mid-Range, and Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , 2019, 7, 65-76.	1.9	62
93	Efficacy and Safety of Spironolactone in Patients With HFpEF and Chronic Kidney Disease. <i>JACC: Heart Failure</i> , 2019, 7, 25-32.	1.9	51
94	Canrenone on cardiovascular mortality in congestive heart failure. <i>Pharmacological Research</i> , 2019, 141, 46-52.	3.1	4
95	Comparison of Outcomes in Patients With Diabetes Mellitus Treated With Versus Without Insulin+ Heart Failure With Preserved Left Ventricular Ejection Fraction (from the TOPCAT Study). <i>American Journal of Cardiology</i> , 2019, 123, 611-617.	0.7	21
96	Impact of mineralocorticoid receptor antagonists on the risk of sudden cardiac death in patients with heart failure and left-ventricular systolic dysfunction: an individual patient-level meta-analysis of three randomized-controlled trials. <i>Clinical Research in Cardiology</i> , 2019, 108, 477-486.	1.5	64
97	Editor's Choice- Impact of insulin-treated diabetes on cardiovascular outcomes following high-risk myocardial infarction. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2019, 8, 231-241.	0.4	22
98	Cardiovascular outcome trials in patients with chronic kidney disease: challenges associated with selection of patients and endpoints. <i>European Heart Journal</i> , 2019, 40, 880-886.	1.0	34
99	Is hyperkalaemia in heart failure a risk factor or a risk marker? Implications for renin-angiotensin-aldosterone system inhibitor use. <i>European Journal of Heart Failure</i> , 2018, 20, 931-932.	2.9	14
100	Sudden Death in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2018, 6, 653-661.	1.9	56
101	The tolerability and safety profile of patiomer: a novel polymer-based potassium binder for the treatment of hyperkalemia. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 525-535.	1.0	14
102	Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish Heart Failure Registry. <i>European Journal of Heart Failure</i> , 2018, 20, 1326-1334.	2.9	156
103	An Evaluation of the Pharmacodynamics, Safety, and Tolerability of the Potassium Binder RDX7675. <i>Journal of Clinical Pharmacology</i> , 2018, 58, 1035-1043.	1.0	2
104	Relation of High Serum Bilirubin to Short-Term Mortality Following a Myocardial Infarction Complicated by Left Ventricular Systolic Dysfunction (from the High-Risk Myocardial Infarction) Tj ETQq0 0 0 rgBT /overlock 10 Tf 50 21		
105	Subcutaneous Furosemide in Heart Failure. <i>JACC Basic To Translational Science</i> , 2018, 3, 25-34.	1.9	27
106	Evaluation of an individualized dose titration regimen of patiomer to prevent hyperkalaemia in patients with heart failure and chronic kidney disease. <i>ESC Heart Failure</i> , 2018, 5, 257-266.	1.4	50
107	Prior Medications and the Cardiovascular Benefits From Combination Angiotensin-Converting Enzyme Inhibition Plus Calcium Channel Blockade Among High-Risk Hypertensive Patients. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	8
108	Stroke Risk in Patients With Reduced Ejection Fraction After Myocardial Infarction Without Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2018, 71, 727-735.	1.2	28

#	ARTICLE	IF	CITATIONS
109	Spironolactone and Resistant Hypertension in Heart Failure With Preserved Ejection Fraction. <i>American Journal of Hypertension</i> , 2018, 31, 407-414.	1.0	26
110	Association between mean systolic and diastolic blood pressure throughout the follow-up and cardiovascular events in acute myocardial infarction patients with systolic dysfunction and/or heart failure: an analysis from the High-Risk Myocardial Infarction Database Initiative. <i>European Journal of Heart Failure</i> , 2018, 20, 323-331.	2.9	23
111	Teasing Apart Heart Failure With Preserved Ejection Fraction Phenotypes With Echocardiographic Imaging. <i>Circulation Research</i> , 2018, 122, 23-25.	2.0	13
112	Individual participant data analysis of two trials on aldosterone blockade in myocardial infarction. <i>Heart</i> , 2018, 104, 1843-1849.	1.2	15
113	Racial Differences in Characteristics and Outcomes of Patients With Heart Failure and Preserved Ejection Fraction in the Treatment of Preserved Cardiac Function Heart Failure Trial. <i>Circulation: Heart Failure</i> , 2018, 11, e004457.	1.6	31
114	Incident Hyperkalemia, Hypokalemia, and Clinical Outcomes During Spironolactone Treatment of Heart Failure With Preserved Ejection Fraction: Analysis of the TOPCAT Trial. <i>Journal of Cardiac Failure</i> , 2018, 24, 313-320.	0.7	49
115	Influence of ejection fraction on cause-specific mortality in heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2018, 20, 815-816.	2.9	5
116	Mineralocorticoid receptor antagonists in patients with acute myocardial infarction – A systematic review and meta-analysis of randomized trials. <i>American Heart Journal</i> , 2018, 195, 60-69.	1.2	21
117	Effect of eplerenone on extracellular cardiac matrix biomarkers in patients with acute ST-elevation myocardial infarction without heart failure: insights from the randomized double-blind REMINDER Study. <i>Clinical Research in Cardiology</i> , 2018, 107, 49-59.	1.5	21
118	Effect of Patiromer on Hyperkalemia Recurrence in Older Chronic Kidney Disease Patients Taking RAAS Inhibitors. <i>American Journal of Medicine</i> , 2018, 131, 555-564.e3.	0.6	38
119	Cardiac Troponin I and Risk of Cardiac Events in Patients With Heart Failure and Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2018, 11, e005312.	1.6	43
120	Future large-scale clinical trials in cardiovascular medicine: challenges and uncertainties. <i>European Journal of Heart Failure</i> , 2018, 20, 1645-1648.	2.9	6
121	Prognostic Value of Albuminuria and Influence of Spironolactone in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2018, 11, e005288.	1.6	35
122	Collagen biomarker bioprofiles predicting the antifibrotic response to eplerenone in myocardial infarction: findings from the REMINDER trial. <i>Clinical Research in Cardiology</i> , 2018, 107, 1192-1195.	1.5	4
123	Association between renin-angiotensin system inhibitor use and mortality/morbidity in elderly patients with heart failure with reduced ejection fraction: a prospective propensity score-matched cohort study. <i>European Heart Journal</i> , 2018, 39, 4257-4265.	1.0	38
124	Revisiting hyperkalaemia guidelines: rebuttal. <i>European Journal of Heart Failure</i> , 2018, 20, 1255-1255.	2.9	2
125	Relation of Serum Potassium to Cardiovascular Events in Patients With Heart Failure and Preserved Ejection Fraction: “Mind the Gap”. <i>American Journal of Hypertension</i> , 2018, 31, 1087-1089.	1.0	3
126	Cost-Effectiveness Analysis of Patiromer and Spironolactone Therapy in Heart Failure Patients with Hyperkalemia. <i>Pharmacoeconomics</i> , 2018, 36, 1463-1473.	1.7	14



#	ARTICLE	IF	CITATIONS
127	Long-term effects of patiomer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin-converting enzymes/angiotensin receptor blockers: results from AMETHYST-ON. ESC Heart Failure, 2018, 5, 592-602.	1.4	45
128	Mineralocorticoid Receptor Antagonists in ST-Segment Elevation Myocardial Infarction. JAMA Internal Medicine, 2018, 178, 920.	2.6	1
129	Visit-to-visit blood pressure variation is associated with outcomes in a U-shaped fashion in patients with myocardial infarction complicated with systolic dysfunction and/or heart failure. Journal of Hypertension, 2018, 36, 1736-1742.	0.3	10
130	Data-Driven Approach to Identify Subgroups of Heart Failure With Reduced Ejection Fraction Patients With Different Prognoses and Aldosterone Antagonist Response Patterns. Circulation: Heart Failure, 2018, 11, e004926.	1.6	26
131	Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction. JACC: Heart Failure, 2018, 6, 689-697.	1.9	68
132	Association of Natriuretic Peptides With Cardiovascular Prognosis in Heart Failure With Preserved Ejection Fraction. JAMA Cardiology, 2018, 3, 1000.	3.0	41
133	Need to revisit heart failure treatment guidelines for hyperkalaemia management during the use of mineralocorticoid receptor antagonists. European Journal of Heart Failure, 2018, 20, 1247-1251.	2.9	17
134	Abstract 278: Trends in Prescribing Patterns for Patients Hospitalized With Heart Failure With Preserved Ejection Fraction Before and After Clinical Trial Presentation. Circulation: Cardiovascular Quality and Outcomes, 2018, 11, .	0.9	0
135	The association between serum potassium and mortality in patients with hypertension: "a wake-up call". European Heart Journal, 2017, 38, ehw209.	1.0	13
136	Characterization of Mineralocorticoid Receptor Antagonist Therapy Initiation in High-Risk Patients With Heart Failure. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, .	0.9	18
137	A Randomized Crossover Trial of Dietary Sodium Restriction in Stage 3-4 CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 399-407.	2.2	69
138	Serum Chloride and Sodium Interplay in Patients With Acute Myocardial Infarction and Heart Failure With Reduced Ejection Fraction. Circulation: Heart Failure, 2017, 10, .	1.6	37
139	Tailoring mineralocorticoid receptor antagonist therapy in heart failure patients: are we moving towards a personalized approach?. European Journal of Heart Failure, 2017, 19, 974-986.	2.9	29
140	Long-Term Effects of Flosequinan on the Morbidity and Mortality of Patients With Severe Chronic Heart Failure. JACC: Heart Failure, 2017, 5, 399-407.	1.9	31
141	Spironolactone Metabolites in TOPCAT " New Insights into Regional Variation. New England Journal of Medicine, 2017, 376, 1690-1692.	13.9	186
142	Association of digitalis treatment with outcomes following myocardial infarction in patients with heart failure or evidence of left ventricular dysfunction: an analysis from the High-Risk Myocardial Infarction Database Initiative. Clinical Research in Cardiology, 2017, 106, 722-733.	1.5	9
143	Physical Activity and Prognosis in the TOPCAT Trial (Treatment of Preserved Cardiac Function Heart) Tj ETQq1 1 0.784314 rgBT /Overbo	1.6	80
144	Prognostic importance of left ventricular mechanical dyssynchrony in heart failure with preserved ejection fraction. European Journal of Heart Failure, 2017, 19, 1043-1052.	2.9	34

#	ARTICLE	IF	CITATIONS
145	Interaction Between Spironolactone and Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2017, 5, 241-252.	1.9	129
146	True rate of mineralocorticoid receptor antagonists-related hyperkalemia in placebo-controlled trials: A meta-analysis. <i>American Heart Journal</i> , 2017, 188, 99-108.	1.2	55
147	Effect of eplerenone in patients with heart failure and reduced ejection fraction: potential effect modification by abdominal obesity. Insight from the EMPHASIS-HF trial. <i>European Journal of Heart Failure</i> , 2017, 19, 1186-1197.	2.9	75
148	Mitochondrial function as a therapeutic target in heart failure. <i>Nature Reviews Cardiology</i> , 2017, 14, 238-250.	6.1	525
149	Prognostic Importance of Temporal Changes in Resting Heart Rate in Heart Failure and Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2017, 5, 782-791.	1.9	21
150	Potassium homeostasis in health and disease: A scientific workshop cosponsored by the National Kidney Foundation and the American Society of Hypertension. <i>Journal of the American Society of Hypertension</i> , 2017, 11, 783-800.	2.3	81
151	Potassium Homeostasis in Health and Disease: A Scientific Workshop Cosponsored by the National Kidney Foundation and the American Society of Hypertension. <i>American Journal of Kidney Diseases</i> , 2017, 70, 844-858.	2.1	53
152	Sodium and Fluid Excretion With Torsemide in Healthy Subjects is Limited by the Short Duration of Diuretic Action. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	21
153	Serum potassium in patients with chronic heart failure: once we make a U-turn where should we go?. <i>European Heart Journal</i> , 2017, 38, 2897-2899.	1.0	12
154	Impact of eplerenone on cardiovascular outcomes in heart failure patients with hypokalaemia. <i>European Journal of Heart Failure</i> , 2017, 19, 792-799.	2.9	34
155	Association of beta-blocker treatment with mortality following myocardial infarction in patients with chronic obstructive pulmonary disease and heart failure or left ventricular dysfunction: a propensity matched-cohort analysis from the High-Risk Myocardial Infarction Database Initiative. <i>European Journal of Heart Failure</i> , 2017, 19, 271-279.	2.9	32
156	Potassium lowering agents: Recommendations for physician and patient education, treatment reappraisal, and serial monitoring of potassium in patients with chronic hyperkalemia. <i>Pharmacological Research</i> , 2017, 118, 2-4.	3.1	26
157	Mineralocorticoid receptor antagonists in patients with heart failure: current experience and future perspectives. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2017, 3, 48-57.	1.4	73
158	Mineralocorticoid Receptor Antagonists in High-Risk Heart Failure Patients With Diabetes Mellitus and/or Chronic Kidney Disease. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	6
159	Expert Panel Recommendations for the Identification and Management of Hyperkalemia and Role of Patiomer in Patients with Chronic Kidney Disease and Heart Failure. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2017, 23, S10-S19.	0.5	19
160	Renal function estimation and Cockcroft-Gault formulas for predicting cardiovascular mortality in population-based, cardiovascular risk, heart failure and post-myocardial infarction cohorts: The Heart & Mics in AGEing (HOMAGE) and the high-risk myocardial infarction database initiatives. <i>BMC Medicine</i> , 2016, 14, 181.	2.3	48
161	New approaches to hyperkalemia in patients with indications for renin angiotensin aldosterone inhibitors: Considerations for trial design and regulatory approval. <i>International Journal of Cardiology</i> , 2016, 216, 46-51.	0.8	20
162	MRAs in Patients With AMI Without Early Evidence of Heart Failure. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1928-1930.	1.2	2

#	ARTICLE	IF	CITATIONS
163	Recent advances in pharmacological treatments of hyperkalemia: focus on patiromer. Expert Opinion on Pharmacotherapy, 2016, 17, 1435-1448.	0.9	26
164	The safety of mineralocorticoid receptor antagonists (MRAs) in patients with heart failure. Expert Opinion on Drug Safety, 2016, 15, 659-665.	1.0	13
165	Prognostic Relevance of Left Atrial Dysfunction in Heart Failure With Preserved Ejection Fraction. Circulation: Heart Failure, 2016, 9, e002763.	1.6	224
166	Hyperkalemia in Heart Failure. Journal of the American College of Cardiology, 2016, 68, 1575-1589.	1.2	86
167	Emergency management of severe hyperkalemia: Guideline for best practice and opportunities for the future. Pharmacological Research, 2016, 113, 585-591.	3.1	91
168	Prognostic Value of the Thrombolysis in Myocardial Infarction Risk Score in ST-Elevation Myocardial Infarction Patients With Left Ventricular Dysfunction (from the EPHEBUS Trial). American Journal of Cardiology, 2016, 118, 1442-1447.	0.7	8
169	Response to: Hyperkalaemia in heart failure: binding the patient to improved treatment?. European Journal of Heart Failure, 2016, 18, 216-216.	2.9	1
170	A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. European Heart Journal, 2016, 37, 2105-2114.	1.0	274
171	Effect of Patiromer on Urinary Ion Excretion in Healthy Adults. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 1769-1776.	2.2	44
172	Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside. Handbook of Experimental Pharmacology, 2016, 243, 271-305.	0.9	102
173	Roadmap for cardiovascular prevention trials in chronic kidney disease. Lancet, The, 2016, 388, 1964-1966.	6.3	13
174	Exploring New Endpoints for Patients With Heart Failure With Preserved Ejection Fraction. Circulation: Heart Failure, 2016, 9, .	1.6	46
175	Heart Failure Clinical Trials in East and Southeast Asia. JACC: Heart Failure, 2016, 4, 419-427.	1.9	48
176	Aspirin does not reduce the clinical benefits of the mineralocorticoid receptor antagonist eplerenone in patients with systolic heart failure and mild symptoms: an analysis of the EMPHASIS-HF study. European Journal of Heart Failure, 2016, 18, 1175-1181.	2.9	12
177	Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors. European Journal of Heart Failure, 2015, 17, 1057-1065.	2.9	134
178	Serum uric acid is associated with mortality and heart failure hospitalizations in patients with complicated myocardial infarction: findings from the High-Risk Myocardial Infarction Database Initiative. European Journal of Heart Failure, 2015, 17, 1144-1151.	2.9	84
179	MY APPROACH to patients with heart failure and a normal ejection fraction. Trends in Cardiovascular Medicine, 2015, 25, 164-165.	2.3	0
180	Regional Variation in Patients and Outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) Trial. Circulation, 2015, 131, 34-42.	1.6	758

#	ARTICLE	IF	CITATIONS
181	A reappraisal of loop diuretic choice in heart failure patients. <i>American Heart Journal</i> , 2015, 169, 323-333.	1.2	83
182	Contemporary Drug Development in Heart Failure. <i>Circulation: Heart Failure</i> , 2015, 8, 826-831.	1.6	34
183	Using Natriuretic Peptides for Selection of Patients in Acute Heart Failure Clinical Trials. <i>American Journal of Cardiology</i> , 2015, 116, 1304-1310.	0.7	5
184	Prognostic Importance of Impaired Systolic Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone. <i>Circulation</i> , 2015, 132, 402-414.	1.6	371
185	Clinical benefits of eplerenone in patients with systolic heart failure and mild symptoms when initiated shortly after hospital discharge: analysis from the EMPHASIS-HF trial. <i>European Heart Journal</i> , 2015, 36, 2310-2317.	1.0	30
186	Rationale and design of Mineralocorticoid Receptor antagonist Tolerability Study in Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease. <i>European Journal of Heart Failure</i> , 2015, 17, 224-232.	2.9	74
187	Improving cardiovascular clinical trials conduct in the United States: Recommendation from clinicians, researchers, sponsors, and regulators. <i>American Heart Journal</i> , 2015, 169, 305-314.	1.2	20
188	Cardiovascular Drug Development. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1567-1582.	1.2	168
189	Patient Selection in Heart Failure With Preserved Ejection Fraction Clinical Trials. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1668-1682.	1.2	116
190	Prognostic Value of Estimated Plasma Volume in Heart Failure. <i>JACC: Heart Failure</i> , 2015, 3, 886-893.	1.9	101
191	Consistency of Laboratory Monitoring During Initiation of Mineralocorticoid Receptor Antagonist Therapy in Patients With Heart Failure. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 1973.	3.8	53
192	Patiromer induces rapid and sustained potassium lowering in patients with chronic kidney disease and hyperkalemia. <i>Kidney International</i> , 2015, 88, 1427-1433.	2.6	90
193	Prognostic Importance of Changes in Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone. <i>Circulation: Heart Failure</i> , 2015, 8, 1052-1058.	1.6	70
194	New Potassium Binders for the Treatment of Hyperkalemia. <i>Hypertension</i> , 2015, 66, 731-738.	1.3	63
195	Mineralocorticoid Receptor Antagonists for the Treatment of Hypertension and the Metabolic Syndrome. <i>Hypertension</i> , 2015, 65, 41-42.	1.3	6
196	Cost-effectiveness of eplerenone in patients with systolic heart failure and mild symptoms. <i>Heart</i> , 2014, 100, 1681-1687.	1.2	26
197	Time to retrieve the best benefits from renin angiotensin aldosterone system (RAAS) inhibition in heart failure patients with reduced ejection fraction: Lessons from randomized controlled trials and registries. <i>International Journal of Cardiology</i> , 2014, 177, 731-733.	0.8	19
198	Geographic variation in heart failure trials: time for scepticism?. <i>European Journal of Heart Failure</i> , 2014, 16, 601-602.	2.9	17

#	ARTICLE	IF	CITATIONS
199	Predictors of contemporary coronary artery bypass grafting outcomes. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2014, 148, 2720-2726.e2.	0.4	25
200	Noncardiac Comorbidities in Heart Failure With Reduced Versus Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2014, 64, 2281-2293.	1.2	424
201	Cardiac Structure and Function and Prognosis in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2014, 7, 740-751.	1.6	218
202	Incidence, Predictors, and Outcomes Related to Hypo- and Hyperkalemia in Patients With Severe Heart Failure Treated With a Mineralocorticoid Receptor Antagonist. <i>Circulation: Heart Failure</i> , 2014, 7, 573-579.	1.6	155
203	Mineralocorticoid Receptor Antagonists in Patients With End-Stage Renal Disease on Chronic Hemodialysis. <i>Journal of the American College of Cardiology</i> , 2014, 63, 537-538.	1.2	24
204	Spironolactone for Heart Failure with Preserved Ejection Fraction. <i>New England Journal of Medicine</i> , 2014, 370, 1383-1392.	13.9	1,993
205	Developing Therapies for Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2014, 2, 97-112.	1.9	267
206	Decongestion in acute heart failure. <i>European Journal of Heart Failure</i> , 2014, 16, 471-482.	2.9	113
207	Effect of Spironolactone on 30-Day Death and Heart Failure Rehospitalization (from the COACH) Tj ETQq1 1 0.784314 rgBT /Overlock 0.7 61	0.7	61
208	Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: The Randomized Double-Blind Reminder Study. <i>European Heart Journal</i> , 2014, 35, 2295-2302.	1.0	128
209	Heart failure: the role for mineralocorticoid receptor antagonists. <i>Swiss Medical Weekly</i> , 2014, 144, w13959.	0.8	7
210	The past, present and future of renin-angiotensin aldosterone system inhibition. <i>International Journal of Cardiology</i> , 2013, 167, 1677-1687.	0.8	97
211	Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. <i>European Heart Journal</i> , 2013, 34, 2453-2463.	1.0	419
212	Rationale and design of ARTS: a randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease. <i>European Journal of Heart Failure</i> , 2012, 14, 668-675.	2.9	72
213	The Role of Mineralocorticoid Receptor Antagonists in Patients with American College of Cardiology/American Heart Association Stage B Heart Failure. <i>Heart Failure Clinics</i> , 2012, 8, 247-253.	1.0	5
214	The role of mineralocorticoid receptor antagonists (MRAs) in very old patients with heart failure. <i>Heart Failure Reviews</i> , 2012, 17, 573-579.	1.7	13
215	Comparison of Lipid-Modifying Efficacy of Rosuvastatin Versus Atorvastatin in Patients With Acute Coronary Syndrome (from the LUNAR Study). <i>American Journal of Cardiology</i> , 2012, 109, 1239-1246.	0.7	49
216	Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms. <i>New England Journal of Medicine</i> , 2011, 364, 11-21.	13.9	2,491

#	ARTICLE	IF	CITATIONS
217	Clinical efficacy of aldosterone-blocking agents. <i>European Heart Journal Supplements</i> , 2011, 13, B36-B39.	0.0	4
218	Male gender, diabetes, COPD, anemia, and creatinine clearance <math>\leq 30\text{ mL/min}</math> predicted hospitalization after heart failure diagnosis. <i>Annals of Internal Medicine</i> , 2010, 152, JC4.	2.0	6
219	Review: Remote patient monitoring of patients with heart failure reduces mortality and heart failure admissions. <i>Annals of Internal Medicine</i> , 2010, 152, JC4.	2.0	2
220	RAAS inhibition/blockade in patients with cardiovascular disease: implications of recent large-scale randomised trials for clinical practice. <i>Heart</i> , 2009, 95, 1205-1208.	1.2	6
221	Cardiovascular effects of aldosterone blockade in CKD. <i>Nature Reviews Cardiology</i> , 2009, 6, 679-680.	6.1	5
222	Multiple renin-angiotensin-aldosterone-blocking agents in heart failure: How much is too much?. <i>Current Heart Failure Reports</i> , 2009, 6, 112-116.	1.3	2
223	Medical therapy versus percutaneous coronary interventions for patients with stable and unstable coronary artery disease. <i>Current Atherosclerosis Reports</i> , 2008, 10, 288-294.	2.0	1
224	Lipid Levels After Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2008, 51, 1440-1445.	1.2	134
225	Aldosterone Blockade in Patients with Chronic Heart Failure. <i>Cardiology Clinics</i> , 2008, 26, 15-21.	0.9	9
226	N-terminal pro-B-type natriuretic peptide concentrations $\geq 100\text{ ng/l}$ increased risk of all-cause mortality. <i>Evidence-Based Medicine</i> , 2008, 13, 26-26.	0.6	0
227	History of Hypertension and Eplerenone in Patients With Acute Myocardial Infarction Complicated by Heart Failure. <i>Hypertension</i> , 2008, 52, 271-278.	1.3	22
228	Added Benefit of Mineralocorticoid Receptor Blockade in the Primary Prevention of Sudden Cardiac Death. <i>Circulation</i> , 2007, 115, 2976-2982.	1.6	25
229	Percutaneous coronary intervention plus optimal medical therapy was not more effective than medical therapy alone in stable CAD. <i>Evidence-Based Medicine</i> , 2007, 12, 107-107.	0.6	0
230	Percutaneous coronary intervention plus optimal medical therapy was not more effective than medical therapy alone in stable CAD. <i>ACP Journal Club</i> , 2007, 147, 12.	0.1	0
231	A primer on aldosterone for gynecologists/obstetricians. <i>Journal of reproductive medicine, The</i> , 2007, 52, 153-8.	0.2	0
232	Percutaneous coronary intervention plus optimal medical therapy was not more effective than medical therapy alone in stable CAD. <i>ACP Journal Club</i> , 2007, 147, 12.	0.1	0
233	Aldosterone receptor antagonists for heart failure: current status, future indications.. <i>Cleveland Clinic Journal of Medicine</i> , 2006, 73, 257-260.	0.6	9
234	Should chronic heart failure patients with reduced left-ventricular ejection fraction receive angiotensin-receptor blockers?. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2005, 2, 70-71.	3.3	0

#	ARTICLE	IF	CITATIONS
235	Role of Aldosterone Blockade in Heart Failure. <i>Heart Failure Clinics</i> , 2005, 1, 49-56.	1.0	1
236	Eplerenone Reduces Mortality 30 Days After Randomization Following Acute Myocardial Infarction in Patients With Left Ventricular Systolic Dysfunction and Heart Failure. <i>Journal of the American College of Cardiology</i> , 2005, 46, 425-431.	1.2	350
237	Generic drugs in cardiology: will they reduce health care costs?. <i>Journal of the American College of Cardiology</i> , 2004, 44, 10-13.	1.2	16
238	Effect of aldosterone blockade in patients with systolic left ventricular dysfunction: implications of the RALES and EPHEBUS studies. <i>Molecular and Cellular Endocrinology</i> , 2004, 217, 53-58.	1.6	101
239	Effects of drospirenone/estradiol on blood pressure and serum potassium in hypertensive postmenopausal women at risk for hyperkalemia. <i>American Journal of Hypertension</i> , 2004, 17, S162.	1.0	0
240	Task Force 2: Investigator Participation in Clinical Research. <i>Circulation</i> , 2004, 110, 2517-2524.	1.6	1
241	Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction. <i>New England Journal of Medicine</i> , 2003, 348, 1309-1321.	13.9	4,403
242	Rofecoxib, but not celecoxib or naproxen, increases mean 24-hour systolic blood pressure: results of a randomized double blind controlled trial in treated hypertensive patients with osteoarthritis (OA) and type 2 diabetes mellitus. <i>American Journal of Hypertension</i> , 2003, 16, A11.	1.0	3
243	Mineralocorticoid receptor blockade: new insights into the mechanism of action in patients with cardiovascular disease. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2003, 4, 164-168.	1.0	47
244	Aldosterone Blockade in Patients With Systolic Left Ventricular Dysfunction. <i>Circulation</i> , 2003, 108, 1790-1794.	1.6	51
245	Do diuretics and aldosterone receptor antagonists improve ventricular remodeling?. <i>Journal of Cardiac Failure</i> , 2002, 8, S491-S493.	0.7	8
246	Clinical trials of angiotensin receptor blockers in heart failure: what do we know and what will we learn?. <i>American Journal of Hypertension</i> , 2002, 15, S22-S27.	1.0	19
247	The role of ACE-inhibitors in patients with coronary artery disease. , 2001, 15, 103-105.		0
248	The EPHEBUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study. <i>Cardiovascular Drugs and Therapy</i> , 2001, 15, 79-87.	1.3	306
249	Specialized Heart Failure Centers—A Success or an Indicator of the Failure of Our Health Care Delivery System. <i>Clinical Cardiology</i> , 2000, 23, 881-882.	0.7	5
250	Risk Stratification for the Detection of Preclinical Coronary Artery Disease. <i>Circulation</i> , 1999, 99, 2610-2612.	1.6	35
251	Title is missing!. <i>Heart Failure Reviews</i> , 1999, 3, 221-232.	1.7	6
252	The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure. <i>New England Journal of Medicine</i> , 1999, 341, 709-717.	13.9	8,093

#	ARTICLE	IF	CITATIONS
253	Specific Impairment of Endothelium-Dependent Vasodilation in Subjects with Type 2 Diabetes Independent of Obesity <sup>1</sup> . <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998, 83, 1946-1952.	1.8	124
254	Quinapril Prevents Hypertension and Enhanced Vascular Reactivity in Nitroarginine-treated Rats. <i>Blood Pressure</i> , 1997, 6, 117-124.	0.7	14
255	Effect of ACE inhibitors on endothelial dysfunction: Unanswered questions and implications for further investigation and therapy. <i>Cardiovascular Drugs and Therapy</i> , 1996, 10, 469-473.	1.3	12
256	Reduction in Cardiovascular Events During Pravastatin Therapy. <i>Circulation</i> , 1995, 92, 2419-2425.	1.6	240
257	An Automated System for ST Segment and Arrhythmia Analysis in Exercise Radionuclide Ventriculography. <i>IEEE Transactions on Biomedical Engineering</i> , 1986, BME-33, 585-593.	2.5	21